CRISPR Race Heats Up As Gates, Crossovers Put $120M Into Editas
By Ben Fidler,
Xconomy
| 08. 10. 2015
To this point, the technology known as CRISPR-Cas9 has been a science project, a research tool with enormous potential—and significant questions to answer—on which venture capitalists have placed bets by forming a group of startups. The jackpot: CRISPR-Cas9, a method of performing precise genetic surgery, might yield treatments for a wide array of previously intractable diseases.
We’re still a long way from anybody claiming that prize, though; no CRISPR-Cas9 therapy has ever been tested in a human being, and a whole lot could go wrong when that happens. Emerging technologies, after all, go through their ups and downs. But today some of the biggest names on Wall Street and elsewhere are showing that they like the odds by handing the largest round of funding yet to a CRISPR-Cas9 startup.
Cambridge-based Editas Medicine is announcing a $120 million Series B round led by Bill Gates’s chief advisor for science and technology, Boris Nikolic. The list of financiers teaming with Nikolic reads like a rolodex of so-called crossover investors, who invest in both public and private entities, and corporate venture arms...
Related Articles
By Andrea Chang, Los Angeles Times | 06.04.2024
Peter Diamandis, a week away from turning 63, bounds out of a Starbucks on a recent morning with a cup of decaf, his daily medley of 70 supplement capsules in his pocket and, tucked under his left arm, a box...
By Shelly Fan, Singularity Hub | 05.31.2024
We all know the drill for reproduction—sperm meets egg.
For the past decade, scientists have been pushing the boundaries of where the two halves come from. Thanks to induced pluripotent stem cell technology, it’s now possible to scrape skin cells...
By Vardit Ravitsky and Louise King, Scientific American | 06.01.2024
Artificial wombs are moving from the realm of science fiction to possible trials with severely premature human babies. We are excited about the great potential benefits of this technology; however, with fetal rights now a political front in the...
By Mariella Bodemeier Loayza Careaga, The Scientist | 03.15.2024
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions of microscopic beings...